store at -20 ℃
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 169.00 | |
2 mg | In stock | $ 249.00 | |
5 mg | In stock | $ 426.00 | |
10 mg | In stock | $ 683.00 | |
25 mg | In stock | $ 997.00 |
Description | Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. |
In vitro | Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to alpha(4)beta(1)-integrin.As a result, leukocyte migration into brain tissue is inhibited, reducing inflammation and preventing the formation of lesions. Natalizumab may also inhibit ongoing central nervous system (CNS) inflammation, mediated by leukocytes already present in the CNS, by interrupting the interactions between α4-integrin-expressing leukocytes and extracellular matrix proteins such as fibronectin and osteopontin[1]. |
Molecular Weight | N/A |
CAS No. | 189261-10-7 |
store at -20 ℃
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Natalizumab 189261-10-7 Cytoskeletal Signaling Integrin inhibit Inhibitor inhibitor